APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuraminidase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025185 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitor Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuraminidase Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuraminidase Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuraminidase Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuraminidase Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuraminidase Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuraminidase Inhibitor Segment by Company

GlaxoSmithKline

Gilead Sciences

F. Hoffman-La Roche

Daiichi Sankyo

BioCryst

Neuraminidase Inhibitor Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitor Segment by Application

Hospital Pharmacies

Drug Stores

Retail Stores

Others

Neuraminidase Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuraminidase Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neuraminidase Inhibitor Industry Trends Table 2. Neuraminidase Inhibitor Industry Drivers Table 3. Neuraminidase Inhibitor Industry Opportunities and Challenges Table 4. Neuraminidase Inhibitor Industry Restraints Table 5. Global Neuraminidase Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neuraminidase Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neuraminidase Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Neuraminidase Inhibitor Sales Market Share by Manufacturers Table 9. Global Neuraminidase Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Neuraminidase Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neuraminidase Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neuraminidase Inhibitor Manufacturers, Product Type & Application Table 13. Global Neuraminidase Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuraminidase Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oseltamivir Table 17. Major Manufacturers of Laninamivir Table 18. Major Manufacturers of Peramivir Table 19. Major Manufacturers of Zanamivir Table 20. Global Neuraminidase Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 22. Global Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 23. Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2026) Table 24. Global Neuraminidase Inhibitor Sales Market Share by Type (2027-2032) Table 25. Global Neuraminidase Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Neuraminidase Inhibitor Revenue by Type (2021-2026) & (K Units) Table 27. Global Neuraminidase Inhibitor Revenue by Type (2027-2032) & (K Units) Table 28. Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2026) Table 29. Global Neuraminidase Inhibitor Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Pharmacies Table 31. Major Manufacturers of Drug Stores Table 32. Major Manufacturers of Retail Stores Table 33. Major Manufacturers of Others Table 34. Global Neuraminidase Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 36. Global Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 37. Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2026) Table 38. Global Neuraminidase Inhibitor Sales Market Share by Application (2027-2032) Table 39. Global Neuraminidase Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Neuraminidase Inhibitor Revenue by Application (2021-2026) & (K Units) Table 41. Global Neuraminidase Inhibitor Revenue by Application (2027-2032) & (K Units) Table 42. Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2026) Table 43. Global Neuraminidase Inhibitor Revenue Market Share by Application (2027-2032) Table 44. Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Neuraminidase Inhibitor Sales by Region (2021-2026) & (K Units) Table 46. Global Neuraminidase Inhibitor Sales Market Share by Region (2021-2026) Table 47. Global Neuraminidase Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Neuraminidase Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 51. North America Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 52. Europe Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 54. Europe Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 61. Global Neuraminidase Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Neuraminidase Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Neuraminidase Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Neuraminidase Inhibitor Revenue Market Share by Region (2021-2026) Table 65. Global Neuraminidase Inhibitor Revenue Market Share by Region (2027-2032) Table 66. GlaxoSmithKline Company Information Table 67. GlaxoSmithKline Business Overview Table 68. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio Table 70. GlaxoSmithKline Recent Development Table 71. Gilead Sciences Company Information Table 72. Gilead Sciences Business Overview Table 73. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Gilead Sciences Neuraminidase Inhibitor Product Portfolio Table 75. Gilead Sciences Recent Development Table 76. F. Hoffman-La Roche Company Information Table 77. F. Hoffman-La Roche Business Overview Table 78. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio Table 80. F. Hoffman-La Roche Recent Development Table 81. Daiichi Sankyo Company Information Table 82. Daiichi Sankyo Business Overview Table 83. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio Table 85. Daiichi Sankyo Recent Development Table 86. BioCryst Company Information Table 87. BioCryst Business Overview Table 88. BioCryst Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. BioCryst Neuraminidase Inhibitor Product Portfolio Table 90. BioCryst Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Neuraminidase Inhibitor Distributors List Table 94. Neuraminidase Inhibitor Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Neuraminidase Inhibitor Product Image Figure 2. Global Neuraminidase Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuraminidase Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuraminidase Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Neuraminidase Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Neuraminidase Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oseltamivir Image Figure 9. Laninamivir Image Figure 10. Peramivir Image Figure 11. Zanamivir Image Figure 12. Global Neuraminidase Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Neuraminidase Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2032) Figure 15. Global Neuraminidase Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Neuraminidase Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2032) Figure 18. Hospital Pharmacies Image Figure 19. Drug Stores Image Figure 20. Retail Stores Image Figure 21. Others Image Figure 22. Global Neuraminidase Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Neuraminidase Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2032) Figure 25. Global Neuraminidase Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Neuraminidase Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2032) Figure 28. North America Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Neuraminidase Inhibitor Sales Market Share by Country (2021-2032) Figure 30. U.S. Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Neuraminidase Inhibitor Sales Market Share by Country (2021-2032) Figure 35. Germany Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Neuraminidase Inhibitor Sales Market Share by Country (2021-2032) Figure 42. China Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Country (2021-2032) Figure 50. Brazil Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Neuraminidase Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Neuraminidase Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Neuraminidase Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Figure 61. North America Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Figure 63. Europe Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Neuraminidase Inhibitor Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Neuraminidase Inhibitor Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacies
  • Drug Stores
  • Retail Stores
  • Others
Companies covered
  • GlaxoSmithKline
  • Gilead Sciences
  • F. Hoffman-La Roche
  • Daiichi Sankyo
  • BioCryst

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuraminidase Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuraminidase Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neuraminidase Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neuraminidase Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neuraminidase Inhibitor Market Dynamics
  1. 2.1 Neuraminidase Inhibitor Industry Trends
  2. 2.2 Neuraminidase Inhibitor Industry Drivers
  3. 2.3 Neuraminidase Inhibitor Industry Opportunities and Challenges
  4. 2.4 Neuraminidase Inhibitor Industry Restraints
3 Neuraminidase Inhibitor Market by Manufacturers
  1. 3.1 Global Neuraminidase Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neuraminidase Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neuraminidase Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neuraminidase Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuraminidase Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neuraminidase Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global Neuraminidase Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuraminidase Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuraminidase Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuraminidase Inhibitor Tier 1, Tier 2, and Tier 3
4 Neuraminidase Inhibitor Market by Type
  1. 4.1 Neuraminidase Inhibitor Type Introduction
  2. 4.1.1 Oseltamivir
  3. 4.1.2 Laninamivir
  4. 4.1.3 Peramivir
  5. 4.1.4 Zanamivir
  6. 4.2 Global Neuraminidase Inhibitor Sales by Type
  7. 4.2.1 Global Neuraminidase Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neuraminidase Inhibitor Sales by Type (2021-2032)
  9. 4.2.3 Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2032)
  10. 4.3 Global Neuraminidase Inhibitor Revenue by Type
  11. 4.3.1 Global Neuraminidase Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Neuraminidase Inhibitor Revenue by Type (2021-2032)
  13. 4.3.3 Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2032)
5 Neuraminidase Inhibitor Market by Application
  1. 5.1 Neuraminidase Inhibitor Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Retail Stores
  5. 5.1.4 Others
  6. 5.2 Global Neuraminidase Inhibitor Sales by Application
  7. 5.2.1 Global Neuraminidase Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neuraminidase Inhibitor Sales by Application (2021-2032)
  9. 5.2.3 Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2032)
  10. 5.3 Global Neuraminidase Inhibitor Revenue by Application
  11. 5.3.1 Global Neuraminidase Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neuraminidase Inhibitor Revenue by Application (2021-2032)
  13. 5.3.3 Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2032)
6 Global Neuraminidase Inhibitor Sales by Region
  1. 6.1 Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuraminidase Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Neuraminidase Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global Neuraminidase Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neuraminidase Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neuraminidase Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neuraminidase Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neuraminidase Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neuraminidase Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neuraminidase Inhibitor Revenue by Region
  1. 7.1 Global Neuraminidase Inhibitor Revenue by Region
  2. 7.1.1 Global Neuraminidase Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neuraminidase Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global Neuraminidase Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global Neuraminidase Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neuraminidase Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neuraminidase Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neuraminidase Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neuraminidase Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neuraminidase Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline
  2. 8.1.1 GlaxoSmithKline Company Information
  3. 8.1.2 GlaxoSmithKline Business Overview
  4. 8.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
  6. 8.1.5 GlaxoSmithKline Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 F. Hoffman-La Roche
  14. 8.3.1 F. Hoffman-La Roche Company Information
  15. 8.3.2 F. Hoffman-La Roche Business Overview
  16. 8.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
  18. 8.3.5 F. Hoffman-La Roche Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 BioCryst
  26. 8.5.1 BioCryst Company Information
  27. 8.5.2 BioCryst Business Overview
  28. 8.5.3 BioCryst Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BioCryst Neuraminidase Inhibitor Product Portfolio
  30. 8.5.5 BioCryst Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuraminidase Inhibitor Value Chain Analysis
  2. 9.1.1 Neuraminidase Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuraminidase Inhibitor Production Mode & Process
  6. 9.2 Neuraminidase Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuraminidase Inhibitor Distributors
  9. 9.2.3 Neuraminidase Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst